656P - Results of a prospective, multicenter, non-interventional trial to analyze disease- and treatment-related effects on the functionality of patients...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastrointestinal Cancers
Presenter Jan Hofmann
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors J. Hofmann1, N. Härtel1, J. Hofmann1, M. Neugebauer1, A. Berger2, S. Zschäbitz2, H. Schulze-Bergkamen3, J. Betge1, S. Belle1, R. Jesenofsky1, N. Schulte1, U. Wedding4, M. Ebert1, J. Chi-Kern1
  • 1Ii. Medizinische Klinik, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 2Medical Oncology, National Center for Tumor Diseases, Heidelberg/DE
  • 3Department For Internal Medicine 2, Marien-Hospital Wesel, 46483 - Wesel/DE
  • 4Department For Internal Medicine 2, Klinik fuer Innere Medizin II Klinikum der Friedrich- Schiller-Universitaet, 07743 - Jena/DE



Cancer is a disease of the elderly (average age of onset >69yrs). However, there is few data available on treatment- and disease-related interactions with the functional reserve of these patients (pts).


Prospective, multicenter non-interventional trial at two university hospitals in Germany. Included were pts ≥ 75yrs (n = 30) with gastrointestinal tumors receiving chemotherapy “ctx” in the period Q1/2015 - Q1/2016. To objectify the functionality of these pts sequential geriatric assessments (G8-Questionaire, ECOG, IADL, ADL) were performed. The analysis is based on data from 2 patient cohorts (C1: ctx 8 wks, n = 15).


An initial dose reduction tended to stabilize the ADL/IADL of pts with newly initiated ctx (C1) when compared to those pts who received a 100%-dosage initially (p = 0,0986). Less ≥2° toxicities (tox) were detected after initial dose reduction (p = ns). However, at the time of the analysis the tox did not correlate with a deterioration in the IADL or ADL. Pts who started ctx with a pathological G8-Screening ( 8 wks (C2), a continued 100%-dosage did not result in a deterioration in the ADL/IADL (additionally no correlation between tox and the IADL/ADL has been detected). C2 pts with an intial G8 


These data suggest, that dose-escalating strategies maintain the functional reserve of pts ≥75yrs with gastrointestinal tumors. However disease control was the strongest predictor for stabilized functionality.

Clinical trial identification

AIO YMO project

Legal entity responsible for the study



Funded by the government


All authors have declared no conflicts of interest.